This event is no longer available and has been removed by the planner. To find out information about upcoming events, feel free to contact the planner directly.
TARGET AUDIENCE AND PREREQUISITEThis activity has been designed to meet the educational needs of ophthalmologists with a basic knowledge of retinal vein occlusion.
STATEMENT OF NEED: Retinal vein occlusion is the second most common retinal vascular disease. Studies in the literature have implicated vascular endothelial growth factor (VEGF) in human eye diseases characterized by increased vascular permeability and VEGF has been targeted in ocular disorders with the underlying manifestations of ocular neovascularization and/or increased vascular permeability, including diabetic macular edema, macular edema due to branch retinal vein occlusion and central retinal vein occlusion. Additionally, cases of uveitis can cause complications, including swelling of the retina or retinal detachment. Laser photocoagulation has been the only treatment option available to treat macular edema secondary to retinal vascular diseases until recently — off-label use of triamcinolone acetonide and more recently, bevacizumab have been utilized. Emerging drug delivery systems and treatments have been developed for macular edema disease treatment and recent randomized controlled clinical trials to evaluate injections of intravitreal steroids and anti-VEGF agents, as well as steroid-based drug delivery systems, have produced promising results. This educational activity will help to educate retinal specialists on improving their practice in light of ongoing evolutions in this field. Integration of individual clinical expertise with the most recent scientific findings will minimize practice exposure, ensuring the most accurate, efficacious and safest decisions about patient care.
LEARNING OBJECTIVES AND DESIRED RESULT: COMPETENCEOn completion of this educational activity, the participant will be able to:
1. Discuss the link between elevated VEGF levels and the growth and permeability of new vessels.2. Identify newly available options for treating retinal vein occlusion.3. Explain how recent findings related to the treatment of retinal vein occlusion and uveitis can improve and enhance a retinal specialist’s patient care.4. Describe the importance of randomized, controlled clinical trials to evaluate new treatment options.
ACCREDITATION STATEMENT:This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Bert M. Glaser National Retina Institute (NRI) and Review of Ophthalmology/Jobson. The NRI is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT:The Bert M. Glaser National Retina Institute designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
SPECIAL NEEDS STATEMENT:The Bert M. Glaser National Retina Institute is committed to making its activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service.